ABBV Dividend History: 2.59% Yield · $1.73 quarterly | MerryDiv
📈 ABBV offers a current dividend yield of 2.59% with an annual payout of $6.83 per share and a quarterly payment of $1.73.
📉 The company's trailing payout ratio stands at 189.7%, indicating that earnings alone do not currently cover the dividend payments.
📊 ABBV has maintained a streak of dividend growth for over 11 consecutive years, with a historical CAGR of 12.5% from 2013 to 2025.
🛡️ The stock displays low volatility with a beta of 0.281, appealing to income investors who prioritize price stability over capital gains.
💊 AbbVie's revenue is driven by a diversified portfolio including blockbuster drugs like HUMIRA, SKYRIZI, and RINVOQ across multiple therapeutic areas.
📅 The next ex-dividend date for ABBV is scheduled for October 15, 2026.
Bullish Signals
- AbbVie has increased its dividend for over 11 consecutive years, demonstrating a strong track record of commitment to shareholder returns.
- The current dividend yield of 2.59% is slightly above the company's five-year average of 2.25%, offering attractive income relative to historical norms.
- ABBV exhibits low market volatility with a beta of 0.281, making it suitable for investors seeking price stability alongside dividend income.
Risk Factors
- The trailing payout ratio is 189.7%, meaning current earnings alone do not cover the dividend, creating potential sustainability risks if earnings decline.
- Investors must rely on free cash flow or forward earnings estimates rather than trailing EPS to accurately assess the safety of ABBV's dividend payments.
Full Analysis
AbbVie Inc. (ABBV) is a global biopharmaceutical company with a current dividend yield of 2.59% based on a $6.83 annual payout and a share price of $263.37. The company has increased its dividend for over 11 consecutive years, demonstrating a long history of commitment to shareholder returns despite recent earnings volatility.
The article highlights a significant concern regarding ABBV's trailing payout ratio of 189.7%, which indicates that current earnings alone do not cover the dividend payment. Analysts and investors are advised to scrutinize this metric, noting that free cash flow coverage and forward earnings estimates may provide a more accurate picture of dividend safety than trailing EPS in this specific context.
Historically, ABBV has shown strong dividend growth with a compound annual growth rate (CAGR) of 12.5% from 2013 to 2025. While the current yield is slightly above its five-year average, the elevated payout ratio creates pressure on sustainability if earnings do not expand or if the company faces setbacks in its blockbuster drug portfolio.
AbbVie's diversified therapeutic portfolio includes major products like HUMIRA, SKYRIZI, and RINVOQ across immunology, oncology, and neurology. The stock exhibits low volatility with a beta of 0.281, making it attractive to income investors seeking price stability, though the high payout ratio remains the primary risk factor for long-term dividend sustainability.
